Trial Profile
An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness in Subjects With Xerostomia Related to Sjogren's Syndrome
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 24 Apr 2019
Price :
$35
*
At a glance
- Drugs 552 02 (Primary)
- Indications Xerostomia
- Focus Therapeutic Use
- Sponsors Parion Sciences
- 14 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 May 2014 New trial record